Document text
Principal Investigator: Rebecca Bradford
Organization: AMERICAN TYPE CULTURE COLLECTION
Fiscal Year: 2022
Award: $3,862,721
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary:
The proposed project aims to renovate ATCC's High Containment Facility (HCF) at the American
Type Culture Collection (ATCC) in Manassas, Virginia. ATCC's 7,500 ft2 biocontainment facility
was built in 2007 with funding from NIAID and has been dedicated to developing infectious
disease strains and reagents needed to rapidly advance diagnostics, vaccines, and therapeutics
against priority pathogens. Since 2003, ATCC has partnered with NIAID to centralize and provide
critical scientific resources through the Biodefense and Emerging Infections Resources (BEI
Resources) program. The NIAID established BEI Resources to provide the global research
community with reagents, tools, and information for studying Category A, B, and C priority
pathogens, emerging infectious disease agents, and other microbiological materials relevant to
human health. Over the past 18 years, ATCC has provided over 1,360,000 reagents to over
14,000 investigators at 3,740 institutions in 119 countries spanning over 500 human pathogens
in NIAID's priority portfolio. During this period, BEI Resources has provided critical materials for
vital disease outbreaks, including H1N1, MERS, Ebola, and Zika. Over the past two years, ATCC
has rapidly created more than 690 SARS-CoV-2 products; acquired, produced, and authenticated
more than 165 stocks of SARS-CoV-2 for both general research and challenge studies; and
shipped more than 86,000 research reagents to over 2,800 researchers in more than 70 countries
for the development of countermeasures and basic research. The material provided by BEI
Resources has been cited in more than 1,800 SARS-CoV-2 publications since February of 2020.
In addition, ATCC has fostered collaboration and partnerships across NIAID programs and
external working groups to share resources, information, and data to accelerate discoveries and
harmonize scientific approaches for pandemic response and preparedness.
ATCC's high containment facility houses laboratories essential for BSL-3 and Select Agent
infectious disease research, product development, and large-scale reagent production for the
research community. This proposal aims to renovate and upgrade the HVAC, decontamination,
and security systems. The renovations also include upgrades to fixed equipment and interior
finishing in the facility. The renovations will modernize the facility for use by 40 Ph.D. ATCC
scientists, collaborators, and laboratory support staff. The products and services developed in the
facility will support thousands of scientists globally each year to prepare and respond to
pandemics. ATCC is seeking this opportunity for engagement with the NIAID to invest in this
facility which has been foundational for the nation's pandemic response and preparedness.
Terms: <2-dimensional><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-D><3-Dimensional><3D><Air Conditioning><Alpha Virus><Alphavirus><American Type Culture Collection><Animals><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Basic Research><Basic Science><Bioassay><Biologic Assays><Biological Assay><Bunyavirus><COVID-19><COVID-19 virus><COVID19><COVID19 virus><CV-19><CV19><Categories><CoV-2><CoV2><Collaborations><Communicable Diseases><Communities><Computer Security><Containment><Coronaviridae><Coronavirus><Country><Data><Decontamination><Development><Diagnostic><Dimensions><Disease Outbreaks><Doctor of Philosophy><Drugs><EBOV><Ebola><Ebola virus><Ebola-like Viruses><Emerging Communicable Diseases><Emerging Infectious Diseases><Equipment><FDA approved><Family><Fostering><Foundations><Funding><Goals><Group A Arboviruses><H1N1><H1N1 Virus><Health><Heating><Human><Infection><Infectious Agent><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Influenza A Virus, H1N1 Subtype><Influenza Virus><Institution><Investigators><Laboratories><Length of Life><Logistics><Longevity><MERS><MERS coronavirus disease><MERS-CoV disease><Medication><Microbiology><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Mission><Modern Man><Modernization><NIAID><National Institute of Allergy and Infectious Disease><Non-Polyadenylated RNA><Orthobunyavirus><Outbreaks><Pathogenesis><Peptides><Ph.D.><PhD><Pharmaceutic Preparations><Pharmaceutical Preparations><Preparedness><Production><Protocol><Protocols documentation><Publications><RNA><RNA Gene Products><RNA Viruses><Readiness><Reagent><Regulation><Research><Research Personnel><Research Resources><Research Support><Researchers><Resource Sharing><Resources><Ribonucleic Acid><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Scientist><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Ships><System><Therapeutic><Translating><Translational Research><Translational Science><Vaccines><Viral><Virginia><Virus><Wuhan coronavirus><ZIKA><ZIKV><Zika Virus><anti-microbial><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antimicrobial><antiviral compound><antiviral medication><antiviral therapeutic><base><biobank><biocontainment facility><biodefense><biorepository><corona virus><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><developmental><drug/agent><ebolavirus><emerging pathogen><facility renovation><hCoV19><human pathogen><in vitro Model><infectious organism><influenzavirus><life span><lifespan><nCoV2><new pathogen><novel><novel pathogen><pandemic><pandemic disease><pandemic preparedness><pathogen><pre-clinical><preclinical><priority pathogen><product development><programs><repair><repaired><response><response biomarker><response markers><screening><small molecule><sq. ft><square foot><system security><three dimensional><tool><translation research><two-dimensional><ventilation><work group><working group><zikav>